Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7547135 | 0.96 | HTR2A (0.42) | HTR2AHTR1ASLC6A4IDO1ADRA1A | |
| SCHEMBL2287390 | 0.89 | LTA4H (0.44) | HTR2AHTR1ASLC6A4 | |
| Benzyl Bromide SCHEMBL7181000 | 0.88 | HTR1A (0.50) | HTR1ASLC6A4 | |
| SCHEMBL7551792 | 0.85 | ADRA1A (0.48) | HTR2AHTR1ASLC6A4IDO1ADRA1A | |
| SCHEMBL30486651 | 0.85 | APLNR (0.46) | HTR2AIDO1ADRA1ATAAR1HPGD | |
| SCHEMBL3527192 | 0.85 | APLNR (0.46) | HTR2AIDO1ADRA1ATAAR1HPGD | |
| SCHEMBL17330013 | 0.84 | HTR1A (0.45) | HTR2AHTR1ASLC6A4IDO1ADRA1A | |
| SCHEMBL2001551 | 0.83 | HSD17B10 (0.44) | HTR2AHTR1ASLC6A4IDO1ADRA1A | |
| SCHEMBL2060421 | 0.83 | HTR2A (0.47) | HTR2AIDO1ADRA1ATAAR1HSD17B10 | |
| SCHEMBL19313248 | 0.82 | GAA (0.53) | HTR2AHTR1ASLC6A4IDO1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117913367-A | Preparation method of composite organic solvent, electrolyte and lithium-sulfur battery | 东方电气集团科学技术研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-1055658-B1 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | CHIU CHARLES K F (US) | 2002-04-11 | — | — | US | claimed |
| US-6323345-B1 | BROMINATING 2-BROMO-5-METHOXY-TOLUENE TO PROVIDE 1-BROMO-2-BROMOMETHYL-4-METHOXYBENZENE; DECARBOXYLATION, REACTING WITH ETHYLENE GLYCOL; REACTING WITH N-BUTYL LITHIUM AND 4-BENZYLOXY BENZONITRILE; HYDROLYSIS, HYDROGENATION | PFIZER INC. | 2001-11-27 | — | — | US | claimed |
| EP-1055658-A2 | Process for cis-1- 2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl pyrrolidine | Pfizer Products Inc. (US) | 2000-11-29 | — | — | EP | claimed |
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4482579-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LHOTSE BIO, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5095129-A | Antiglucocorticoid, antimineralcorticoid, antiandrogen | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0283428-B1 | 19,11-BETA-BRIDGED STEROIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-10-30 | — | — | EP | disclosed |
| EP-0344414-A1 | 5-Substitued imidazo[4,5-c]pyridines | G.D. Searle & Co. (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0283428-A1 | 19,11-Beta-bridged steroids, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | HTR2A 3052/4885HTR1A 3534/4885SLC6A4 2096/4885 |
| US-20020042524-A1 | Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine | P4HA1, PAH, DNM1 | HTR2A 1623/4885HTR1A 307/4885SLC6A4 3721/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | HTR2A 3451/4885HTR1A 4651/4885SLC6A4 4691/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | HTR2A 3052/4885HTR1A 3534/4885SLC6A4 2096/4885 |
| US-12428375-B2 | Compounds and compositions for treating conditions associated with LPA receptor activity | LPAR2, LPAR1, LPAR6 | HTR2A 635/4885HTR1A 1034/4885SLC6A4 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.